EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities

Ming-Da Wang iD, Xue-Jun Xu, Ke-Chun Wang, Yong-Kang Diao, Jia-Hao Xu, Li-Hui Gu, Lan-Qing Yao, Chao Li, Guo-Yue Lv, Tian Yang iD

Cancer Science · 2024-07 · 115 (7) · 2159-2169

DOI: 10.1111/cas.16194 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 02.05.2024. Verfasst von Ming-Da Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Precision Medicine. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Health and Hygiene Discipline Leader Project, Dawn Project Foundation of Shanghai, Shanghai Outstanding Academic Leader Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC), the most prevalent malignancy of the digestive tract, is characterized by a high mortality rate and poor prognosis, primarily due to its initial diagnosis at an advanced stage that precludes any surgical intervention. Recent advancements in systemic therapies have significantly improved oncological outcomes for intermediate and advanced‐stage HCC, and the combination of locoregional and systemic therapies further facilitates tumor downstaging and increases the likelihood of surgical resectability for initially unresectable cases following conversion therapies. This shift toward high conversion rates with novel, multimodal treatment approaches has become a principal pathway for prolonged survival in patients with advanced HCC. However, the field of conversion therapy for HCC is marked by controversies, including the selection of potential surgical candidates, formulation of conversion therapy regimens, determination of optimal surgical timing, and application of adjuvant therapy post‐surgery. Addressing these challenges and refining clinical protocols and research in HCC conversion therapy is essential for setting the groundwork for future advancements in treatment strategies and clinical research. This narrative review comprehensively summarizes the current strategies and clinical experiences in conversion therapy for advanced‐stage HCC, emphasizing the unresolved issues and the path forward in the context of precision medicine. This work not only provides a comprehensive overview of the evolving landscape of treatment modalities for conversion therapy but also paves the way for future studies and innovations in this field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPrecision MedicineHumansCombined Modality TherapyNeoplasm StagingHepatectomy

Stichwörter der Autor:innen

advanced hepatocellular carcinomaconversion therapyimmune checkpoint inhibitorslocoregional treatmentmolecular targeted therapyprognosisresection

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
  • Department of Hepatobiliary Surgery, General Hospital of Xinjiang Military Region of PLA, Urumuqi, Xinjiang, China.
  • Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.

ORCID-Profile: Ming-Da Wang, Tian Yang

Förderung

  • Shanghai Health and Hygiene Discipline Leader Project
  • Dawn Project Foundation of Shanghai
  • Shanghai Outstanding Academic Leader Program
  • National Natural Science Foundation of China
  • Shanghai Science and Technology Committee Rising-Star Program
  • the Natural Science Foundation of Shanghai

Zitieren

APA

Wang, M. D., Xu, X. J., Wang, K. C., Diao, Y. K., Xu, J. H., Gu, L. H., Yao, L. Q., Li, C., Lv, G. Y., & Yang, T. (2024). Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities. Cancer Science, 115(7), 2159-2169. https://doi.org/10.1111/cas.16194

Vancouver

Wang MD, Xu XJ, Wang KC, Diao YK, Xu JH, Gu LH, et al. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities. Cancer Science. 2024;115(7):2159-2169. doi:10.1111/cas.16194

BibTeX
@article{Wang2024,
  author = {Wang, Ming-Da and Xu, Xue-Jun and Wang, Ke-Chun and Diao, Yong-Kang and Xu, Jia-Hao and Gu, Li-Hui and Yao, Lan-Qing and Li, Chao and Lv, Guo-Yue and Yang, Tian},
  title = {Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {7},
  pages = {2159--2169},
  doi = {10.1111/cas.16194}
}
Kostenlos starten →